Antares Pharma Reports Second Quarter 2016 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq futures surge 2% as chip outlook calms AI jitters; inflation data awaited
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Piper Jaffray Cuts Price Target on Antares Pharma (ATRS) Following 2Q
August 11, 2016 8:08 AM EDTPiper Jaffray maintained an Overweight rating on Antares Pharma (NASDAQ: ATRS), and cut the price target to $2.00 (from $3.00), following the company's 2Q earnings report. ATRS reported EPS of ($0.04), in-line with the Street's estimate. Revenues of $12.2M came in ahead of the Street estimates of $10.8M.... More
Antares Pharma (ATRS) Reports In-Line Q2 EPS
August 9, 2016 7:50 AM EDTAntares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $11 million.
For earnings history and earnings-related data on Antares Pharma (ATRS) click here.
... More